Amgen Inc. vs Moderna, Inc. — Stock Comparison

Amgen Inc. (AMGN) and Moderna, Inc. (MRNA) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

Q·Score Winner
Amgen Inc.
AMGN6.7/10vs 4.9/10

Amgen Inc. clearly outscores Moderna, Inc. on Q·Score (6.7 vs 4.9 out of 10), led by Quality (9.3 vs 0.6) and Valuation (7 vs 3). Moderna, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for AMGN (+3.8%) than for MRNA (-7.8%).

Q·Score Breakdown

6.7
Neutral
Overall
4.9
Bearish
9.3
Quality
0.6
4.5
Health
9.4
6.3
Growth
8.3
7
Valuation
3
5.6
Sentiment
3.9
AMGN

High-quality business with 101% return on equity and 21% profit margins.

high leverage at 6.2× debt-to-equity.

MRNA

Clean balance sheet with low leverage (0.2× debt-to-equity).

currently unprofitable (-144% margin).

Analyst Consensus

Neutral
+3.8%
Target $352.23
30 analysts
Neutral
-7.8%
Target $43.20
20 analysts

Fundamentals

AMGN
MRNA
23.6×
Trailing P/E
14.5×
Forward P/E
-11.2×
20.96%
Profit Margin
-143.55%
71.44%
Gross Margin
-69.89%
101.32%
ROE
-36.56%
5.80%
Revenue Growth
260.20%
4.40%
Earnings Growth
0.43
Beta
1.06
2.97%
Dividend Yield
$183.1B
Market Cap
$18.6B
52-Week Range
AMGN
$26858% of range$391
MRNA
$2266% of range$60

Frequently Asked Questions

AMGN vs MRNA: which stock scores better overall?

Based on Q·Score, Amgen Inc. (AMGN) scores 6.7/10 versus Moderna, Inc. (MRNA) at 4.9/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: AMGN or MRNA?

Moderna, Inc. (MRNA) scores higher on Growth (8.3/10 vs 6.3/10). Amgen Inc. reports revenue growth (5.8% YoY) while Moderna, Inc. reports (260.2% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is AMGN or MRNA more attractively valued?

Amgen Inc. (AMGN) scores higher on Valuation (7/10 vs 3/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about AMGN vs MRNA?

There are 30 analysts covering AMGN with a consensus price target of $352.23, and 20 analysts covering MRNA with a consensus target of $43.20. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: AMGN or MRNA?

Amgen Inc. (AMGN) scores higher on Quality (9.3/10 vs 0.6/10). Net profit margin: AMGN at 21.0%, MRNA at -143.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: AMGN or MRNA?

Moderna, Inc. (MRNA) scores higher on Financial Health (9.4/10 vs 4.5/10). Market beta: AMGN at 0.43, MRNA at 1.06. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of AMGN and MRNA?

Amgen Inc. (AMGN) has a market capitalisation of $183.1B, while Moderna, Inc. (MRNA) has a market cap of $18.6B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Do AMGN or MRNA pay dividends?

AMGN pays a dividend yield of 2.97%, while MRNA does not currently pay a dividend. Dividend yields fluctuate with share price and company payout decisions.

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026